MEDICLINIC INTERNATIONAL PLC

Remuneration Information • May 25, 2023

National Storage Mechanism | Additional information

RNS Number : 6902A

Mediclinic International plc

25 May 2023

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

South African income tax number: 9432434182

('Mediclinic', the 'Company', or the 'Group')

25 May 2023

NOTIFICATION: TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES & PERSONS CLOSELY ASSOCIATED WITH THEM

Vesting of awards under the Company's Short-Term Incentive ('STI') scheme and Long-Term Incentive Plan ('LTIP')

In connection with the recommended cash acquisition of Mediclinic by Manta Bidco Limited (a newly formed company owned by: (i) Remgro Limited and certain of its subsidiaries; and (ii) SAS Shipping Agencies Services S.à r.l., a wholly owned subsidiary of MSC Mediterranean Shipping Company SA) (the 'Acquisition'), this notification sets out the details of the vesting of awards over ordinary shares in Mediclinic granted under the Company's STI and LTIP to Directors and other persons discharging managerial responsibilities ('PDMRs') in the financial years ended on 31 March 2020, 31 March 2021, 31 March 2022 and 31 March 2023.

The awards vested on 24 May 2023 and will be settled in cash, based on the offer price to be paid by Manta Bidco Limited in connection with the Acquisition, being 501 pence per share.

The notifications that follow are made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

1.

Details of PDMR / person closely associated with them

a)

Name

Dr Carel Aron van der Merwe

2.

Reason for the notification

a)

Position / status

Group Chief Executive Officer - Mediclinic International plc 

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.1

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:

1.   19 June 2019;

2.   14 December 2020;

3.   4 June 2021; and

4.   5 August 2022.

Vesting of deferred awards over ordinary shares in Mediclinic granted at nil cost under the Company's STI on:

5.   4 June 2021; and

6.   5 August 2022

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1.              £nil	45 185
2.              £nil	176 093
3.              £nil	118 727
4.              £nil	49 524
5.              £nil	122 614
6.              £nil	74 718

d)

Aggregated information

Aggregated volume

Price

586 861

£nil

e)

Date of the transaction

24 May 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of PDMR / person closely associated with them

a)

Name

Petrus Jurgens Myburgh

2.

Reason for the notification

a)

Position / status

Group Chief Financial Officer - Mediclinic International plc  

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.1

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:

1.   19 June 2019;

2.   14 December 2020;

3.   4 June 2021; and

4.   5 August 2022.

Vesting of deferred awards over ordinary shares in Mediclinic granted at nil cost under the Company's STI on:

5.   4 June 2021; and

6.   5 August 2022

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1.              £nil	24 981
2.              £nil	97 549
3.              £nil	63 523
4.              £nil	30 900
5.              £nil	80 655
6.              £nil	47 488

d)

Aggregated information

Aggregated volume

Price

345 096

£nil

e)

Date of the transaction

24 May 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of PDMR / person closely associated with them

a)

Name

Gert Cornelis Hattingh

2.

Reason for the notification

a)

Position / status

Group Chief Governance Officer - Mediclinic International plc 

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:

1.   14 December 2020;

2.   4 June 2021; and

3.   5 August 2022.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1.              £nil	37 839
2.              £nil	24 331
3.              £nil	5 983

d)

Aggregated information

Aggregated volume

Price

68 153

£nil

e)

Date of the transaction

24 May 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of PDMR / person closely associated with them

a)

Name

Dr Dirk Cornelius le Roux

2.

Reason for the notification

a)

Position / status

Group Chief Information Officer - Mediclinic International plc 

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:

1.   14 December 2020;

2.   4 June 2021; and

3.   5 August 2022.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1.              £nil	29 654
2.              £nil	19 053
3.              £nil	4 677

d)

Aggregated information

Aggregated volume

Price

53 384

£nil

e)

Date of the transaction

24 May 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of PDMR / person closely associated with them

a)

Name

Dr Daniel Liedtke

2.

Reason for the notification

a)

Position / status

Chief Executive Officer: Hirslanden

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:

1.   14 December 2020;

2.   4 June 2021; and

3.   5 August 2022.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1.              £nil	70 352
2.              £nil	39 423
3.              £nil	10 849

d)

Aggregated information

Aggregated volume

Price

120 624

£nil

e)

Date of the transaction

24 May 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of PDMR / person closely associated with them

a)

Name

Magnus Oetiker

2.

Reason for the notification

a)

Position / status

Group Chief Strategy Officer - Mediclinic International plc

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:

1.   14 December 2020;

2.   4 June 2021; and

3.   5 August 2022.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1.              £nil	56 587
2.              £nil	32 303
3.              £nil	10 822

d)

Aggregated information

Aggregated volume

Price

99 712

£nil

e)

Date of the transaction

24 May 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of PDMR / person closely associated with them

a)

Name

Koert Hendrik Stefanus Pretorius

2.

Reason for the notification

a)

Position / status

Group Chief Operating Officer - Mediclinic International plc

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:

1.   14 December 2020;

2.   4 June 2021; and

3.   5 August 2022.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1.            £nil	39 509
2.            £nil	25 469
3.            £nil	6 261

d)

Aggregated information

Aggregated volume

Price

71 239

£nil

e)

Date of the transaction

24 May 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of PDMR / person closely associated with them

a)

Name

Dr René Toua

2.

Reason for the notification

a)

Position / status

Group Chief Clinical Officer - Mediclinic International plc

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:

1.   14 December 2020;

2.   4 June 2021; and

3.   5 August 2022.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1.            £nil	30 301
2.            £nil	19 829
3.            £nil	4 915

d)

Aggregated information

Aggregated volume

Price

55 045

£nil

e)

Date of the transaction

24 May 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of PDMR / person closely associated with them

a)

Name

Dr Tyson Bruno Welzel

2.

Reason for the notification

a)

Position / status

Group Chief Innovation Officer - Mediclinic International plc

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:

1.   14 December 2020;

2.   4 June 2021; and

3.   5 August 2022.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1.            £nil	24 080
2.            £nil	15 896
3.            £nil	8 460

d)

Aggregated information

Aggregated volume

Price

48 436

£nil

e)

Date of the transaction

24 May 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of PDMR / person closely associated with them

a)

Name

Hein van Eck

2.

Reason for the notification

a)

Position / status

Chief Executive Officer - Mediclinic Middle East

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:

4.   14 December 2020;

5.   4 June 2021; and

6.   5 August 2022.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
4.            £nil	8 833
5.            £nil	5 011
6.            £nil	2 102

d)

Aggregated information

Aggregated volume

Price

15 946

£nil

e)

Date of the transaction

24 May 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of PDMR / person closely associated with them

a)

Name

Greg van Wyk

2.

Reason for the notification

a)

Position / status

Chief Executive Officer: Mediclinic Southern Africa

b)

Initial notification / amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mediclinic International plc

b)

LEI

2138002S5BSBIZTD5I60

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares

GB00B8HX8Z88

b)

Nature of the transaction

Vesting of conditional awards over ordinary shares in Mediclinic granted at nil cost under the Company's LTIP on:

1.   14 December 2020;

2.   4 June 2021; and

3.   5 August 2022.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
4.            £nil	22 919
5.            £nil	14 800
6.            £nil	5 681

d)

Aggregated information

Aggregated volume

Price

43 400

£nil

e)

Date of the transaction

24 May 2023

f)

Place of the transaction

Outside a trading venue

CONTACT INFORMATION

Investor queries

James Arnold, Head of Investor Relations, Mediclinic International plc

+44 (0)20 3786 8181

ir@mediclinic.com 

Media queries

FTI Consulting

Ben Atwell/Ciara Martin - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBDGDUSBDDGXU